"Angiotensin II Type 1 Receptor Blockers/pharmacokinetics"[MeSH] - Search Results

Year	Number of Results
2002	1
2004	3
2005	16
2006	15
2007	17
2008	18
2009	36
2010	15
2011	19
2012	19
2013	23
2014	14
2015	17
2016	17
2017	18
2018	9
2019	7
2020	8
2021	6
2024	0

1

Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Al-Majed AR, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003. Epub 2015 Apr 9. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051686 Review.

2

Clinical pharmacokinetics of losartan.

Sica DA, Gehr TW, Ghosh S. Sica DA, et al. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. Clin Pharmacokinet. 2005. PMID: 16029066 Review.

3

Telmisartan.

Bakheit AH, Abd-Elgalil AA, Mustafa B, Haque A, Wani TA. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:371-429. doi: 10.1016/bs.podrm.2015.01.003. Epub 2015 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051689 Review.

4

Angiotensin Receptor-Neprilysin Inhibition.

Havakuk O, Elkayam U. Havakuk O, et al. J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):356-364. doi: 10.1177/1074248416683049. Epub 2016 Dec 28. J Cardiovasc Pharmacol Ther. 2017. PMID: 28587583 Review.

5

Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).

Shaddy R, Canter C, Halnon N, Kochilas L, Rossano J, Bonnet D, Bush C, Zhao Z, Kantor P, Burch M, Chen F. Shaddy R, et al. Am Heart J. 2017 Nov;193:23-34. doi: 10.1016/j.ahj.2017.07.006. Epub 2017 Jul 17. Am Heart J. 2017. PMID: 29129252 Free article. Clinical Trial.

6

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.

Hjermitslev M, Grimm DG, Wehland M, Simonsen U, Krüger M. Hjermitslev M, et al. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):225-233. doi: 10.1111/bcpt.12800. Epub 2017 Jun 19. Basic Clin Pharmacol Toxicol. 2017. PMID: 28444983 Free article. Review.

7

Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.

Ahad A, Al-Mohizea AM, Al-Jenoobi FI, Aqil M. Ahad A, et al. Drug Deliv. 2016;23(2):579-90. doi: 10.3109/10717544.2014.942444. Epub 2014 Jul 28. Drug Deliv. 2016. PMID: 25065883 Review.

8

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.

Michel MC, Foster C, Brunner HR, Liu L. Michel MC, et al. Pharmacol Rev. 2013 Mar 13;65(2):809-48. doi: 10.1124/pr.112.007278. Print 2013 Apr. Pharmacol Rev. 2013. PMID: 23487168 Review.

9

Fimasartan, a novel angiotensin II receptor antagonist.

Kim JH, Lee JH, Paik SH, Kim JH, Chi YH. Kim JH, et al. Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z. Arch Pharm Res. 2012. PMID: 22864732 Review.

10

Pharmacokinetic evaluation of losartan.

Burnier M, Wuerzner G. Burnier M, et al. Expert Opin Drug Metab Toxicol. 2011 May;7(5):643-9. doi: 10.1517/17425255.2011.570333. Epub 2011 Mar 22. Expert Opin Drug Metab Toxicol. 2011. PMID: 21417956 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

244 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Results by year